- Paper Report
- Open Access
Endocrine response: Is CGAthe key?
- Valerie Speirs1
© Biomed Central Ltd 2001
- Received: 30 April 2001
- Accepted: 20 August 2001
- Published: 1 December 2001
- CGA, endocrine response, estrogen receptor
Oestrogen receptor (ER) is an established prognostic marker in breast cancer and expressed in about two thirds of all patients. The presence of ER is used routinely to predict response to adjuvant endocrine therapy. However, not all patients with ER-positive tumours respond, so there is a need to identify alternative markers of endocrine responsiveness. In this study, the authors evaluated the role of the CGA gene (coding for the a subunit of glycoprotein) as a novel ER-responsive gene in a cohort of human breast tumours.
Overexpression of CGA was observed in 44 of the 131 breast tumours tested. Significant associations were noted between CGA overexpression and features indicating a low level of biological aggressiveness, including histological grades I and II, ER a and progesterone receptor. Overexpression of CGA was not observed in ER-negative tumours, indicating its association with ER responsiveness, and immunohistochemical analysis showed CGA was expressed exclusively in ER-positive tumour cells.
TaqManR real-time PCR, immunohistochemistry